SELLAS Life Sciences provides galinpepimut-S and nelipepimut-S program update
SELLAS announced the Knight Cancer Institute and Memorial Sloan Kettering Cancer Center will serve as sites for the Phase 1/2 open-label, non-comparative, multicenter, multi-arm study of GPS in combination with Merck’s anti-PD-1 therapy KEYTRUDA® in patients with WT1-positive advanced cancers. February 12, 2019